Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-17T01:24:16.274Z Has data issue: false hasContentIssue false

Commercialisation of a recombinant vaccine against Boophilus microplus

Published online by Cambridge University Press:  06 April 2009

P. Willadsen
Affiliation:
CSIRO Division of Tropical Animal Production, Meiers Rd., Indooroopilly, Queensland, Australia4068
P. Bird
Affiliation:
CSIRO Division of Tropical Animal Production, Meiers Rd., Indooroopilly, Queensland, Australia4068
G. S. Cobon
Affiliation:
Biotech Australia, PO Box 20, Roseville, New South Wales, Australia2069
J. Hungerford
Affiliation:
Biotech Australia, PO Box 20, Roseville, New South Wales, Australia2069

Summary

Increasingly, there is need for methods to control cattle tick (Boophilus microplus) infestations by the use of non-chemical technology. This need is brought about by a mixture of market forces and the failure or inadequacy of existing technology. A recombinant vaccine has now been developed against the tick. This vaccine relies on the uptake with the blood meal of antibody directed against a critical protein in the tick gut. The isolation of the vaccine antigen, Bm86, and its production as a recombinant protein is briefly described. The vaccine has been tested in the field, has been taken through the full registration process and is now in commercial use in Australia. A related development has occurred in Cuba. The potential for improvement of the current vaccine and for the development of similar vaccines against other haematophagous parasites is discussed.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable